Abstract

Corona Virus Disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global pandemic. Currently there is no effective treatment for this disease, vaccination is one way to deal with this disease. Antibodies that are formed after vaccination are expected to provide protection for everyone. This study was to determine the levels of IgG antibodies formed after SARS-CoV-2 vaccination. 87 respondents were examined in this study using blood samples. Measurement of antibody levels using the CLIA method. The results obtained show that the average level of antibodies formed is 193.355 BAU/ml. 65 respondents who received 3 doses of vaccine (199.652 BAU/ml) had higher antibody levels than respondents who received two doses of vaccine (175.531 BAU/ml) and 1 dose of vaccine (158.365 BAU/ml). Antibody levels in respondents who were examined between 0-6 months after vaccination (202.827 BAU/ml) had higher levels than respondents with a period of more than six months (186.010 BAU/ml). From the study results, data was obtained that the antibody levels in recipients of three vaccine doses were higher so that they could provide sustainable protection against COVID-19. Therefore, the COVID-19 vaccine booster should give to all people to provide protection against COVID-19.

There is no Figure or data content available for this article

References

• Organization WH. Coronavirus Disease Coronavirus Disease 2019 ( COVID-19 ) Coronavirus Internal for Disease Situation World Health World Health Organization Organization. 2021;19:1-11.
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
• Soegiarto G, Wulandari L, Purnomosari D, Oceandy D. Evaluasi Efikasi Vaksin COVID-19 Pada Sumber Daya Manusia Kesehatan. J Keperawatan. 2022;14(3):837-844. http://journal.stikeskendal.ac.id/index.php/Keperawatan
• Fajrunni’mah R, , Angki Purwanti, Setiawan B. KADAR ANTIBODI IgG SARS COV-2 SETELAH VAKSINASI. 2023;33(2):44-52.
• Hidayati H, Musniati N, Hidayat A, Nurmansyah MI. Using Health Belief Model for predicting COVID-19 prevention practices among university student and staff. Int J Public Heal Sci. 2022;11(1):20-27. doi:10.11591/ijphs.v11i1.21059
• Ophinni Y, Hasibuan AS, Widhani A, et al. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. Acta Med Indones. 2020;52(4):388-412.
• Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354
• Heidary M, Kaviar VH, Shirani M, et al. A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. Front Microbiol. 2022;13:927306. doi:10.3389/fmicb.2022.927306
• Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020;14(10):12522-12537. doi:10.1021/acsnano.0c07197
• Rosa MFF, da Silva EN, Pacheco C, et al. Direct from the COVID-19 crisis: research and innovation sparks in Brazil. Heal Res Policy Syst. 2021;19(1):1-7. doi:10.1186/s12961-020-00674-x
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81. doi:10.1126/science.abc1932
• Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019;32(2):1-50.
• Gundlapalli A V., Salerno RM, Brooks JT, et al. SARS-CoV-2 serologic assay needs for the next phase of the US COVID-19 pandemic response. Open Forum Infect Dis. 2021;8(1). doi:10.1093/ofid/ofaa555
• Uysal EB, Gümü? S, Bektöre B, Bozkurt H, Gözalan A. Evaluation of antibody response after COVID-19 vaccination of healthcare workers. J Med Virol. 2022;94(3):1060-1066. doi:10.1002/jmv.27420
• Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells. 2021;10(206).
• Dobaño C, Santano R, Jiménez A, et al. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. Transl Res. 2021;232:60-74. doi:10.1016/j.trsl.2021.02.006
• Wang P, Liu L, Nair MS, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020;9(1):2091-2093. doi:10.1080/22221751.2020.1823890
• Salazar E, Kuchipudi S V., Christensen PA, et al. Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020;130(12):6728-6738. doi:10.1172/JCI141206
• Franco-Muñoz C, Álvarez-Díaz DA, Laiton-Donato K, et al. Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in South America. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;85:104557. doi:10.1016/j.meegid.2020.104557
• Pellini R, Venuti A, Pimpinelli F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021;36:100928. doi:10.1016/j.eclinm.2021.100928
• Mitsunaga T, Ohtaki Y, Seki Y, et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: A prospective study in Japan. PeerJ. 2021;9:1-18. doi:10.7717/peerj.12316
• Leys YE, Nwokocha M, Walker JP, et al. SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica. Am J Trop Med Hyg. 2022;106(5):1511-1514. doi:10.4269/ajtmh.21-1128
• Prasetyo ME, Soegiarto G, Wulandari L. Impact of gender difference towards coronavirus disease 2019 ( COVID-19 ) vaccine antibody response?: systematic review. 2024;13(1):95-100. doi:10.15562/bmj.v13i1.4710
• Ward H, Whitaker M, Flower B, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-28527-x
• French MA, Moodley Y. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. Respirology. 2020;25(7):680-682. doi:10.1111/resp.13852
• Allison FI, Ojule AC, Shittu L, Bamigbowu EO. The Effects Of Speed And Duration Of Centrifugation On The Values of Some Commonly Measured Plasma Electrolytes. Eur J Med Heal Sci. 2020;2(2):2-5. doi:10.24018/ejmed.2020.2.2.187
• Cristiano A, Pieri M, Sarubbi S, et al. Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring. Clin Immunol. 2022;234:108918. doi:10.1016/j.clim.2021.108918
• Dundar B, Karahangil K, Elgormus CS, Topsakal HNH. Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactive vaccine against COVID-19. J Med Virol. 2022;94(6):2431-2437. doi:10.1002/jmv.27649
• Dedroogh S, Schmiedl S, Thürmann PA, et al. Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults. Sci Rep. 2023;13(1):9036. doi:10.1038/s41598-023-34961-8
• Terpos E, Trougakos IP, Karalis V, et al. Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162B2; a prospective study in 283 health workers. Cells. 2021;10(8). doi:10.3390/cells10081942
• Trougakos IP, Terpos E, Zirou C, et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021;19(1):1-11. doi:10.1186/s12916-021-02090-6
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407-1416. doi:10.1016/S0140-6736(21)02183-8
• Larkin HD. Two mRNA COVID-19 Vaccines Stimulate Different Immune Responses. JAMA - J Am Med Assoc. 2022;327(18):1748. doi:10.1001/jama.2022.4974
• Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021;384(23):2259-2261. doi:10.1056/nejmc2023298
• Masrika NUE, Nugroho AW, Viwattanakulvanid P, Herman B. Vaccination efficacy against post-COVID-19 symptoms in Delta and Omicron waves: a prospective cohort in East Indonesia. Int J Public Heal Sci. 2023;12(1):32-40. doi:10.11591/ijphs.v12i1.22470
• Pluss O, Campbell H, Pezzi L, et al. Limitations introduced by a low participation rate of SARS-CoV-2 seroprevalence data. Int J Epidemiol. 2023;52(1):32-43. doi:10.1093/ije/dyac178

There is no Supplemental content for this article.

How to Cite This

Article Metrics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability